Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites
This article was originally published in PharmAsia News
Executive Summary
Despite ongoing compliance probes, decelerating growth and continuing price pressure, Merck KGAA and Johnson & Johnson unveil bold localization plans in China with a fresh investment worth millions. They see the need to support essential drug supply, introduce new products and accelerate product registration in China.